Compare MOV & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOV | AVTX |
|---|---|---|
| Founded | 1961 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 878.9M | 982.5M |
| IPO Year | 1996 | 2015 |
| Metric | MOV | AVTX |
|---|---|---|
| Price | $35.83 | $19.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $31.50 | ★ $40.57 |
| AVG Volume (30 Days) | 156.2K | ★ 800.3K |
| Earning Date | 05-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.17% | N/A |
| EPS Growth | 44.44 | ★ 72.07 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $338,600,000.00 | $27,813,137.00 |
| Revenue This Year | $1.92 | N/A |
| Revenue Next Year | $0.67 | N/A |
| P/E Ratio | $122.17 | ★ N/A |
| Revenue Growth | 25.73 | ★ 2312.27 |
| 52 Week Low | $15.70 | $8.41 |
| 52 Week High | $40.50 | $24.27 |
| Indicator | MOV | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 56.08 |
| Support Level | $35.67 | $17.40 |
| Resistance Level | $39.72 | $20.68 |
| Average True Range (ATR) | 1.26 | 1.20 |
| MACD | -0.28 | 0.02 |
| Stochastic Oscillator | 3.61 | 79.32 |
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.